CIM
AGIO icon

Contravisory Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

Contravisory Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,189
Closed -$168K – 372
2025
Q4 		$168K Buy
+6,189
New +$217K 0.03% 234
2025
Q1 		– Sell
-6,752
Closed -$222K – 377
2024
Q4 		$222K Buy
+6,752
New +$317K 0.05% 213
2018
Q1 		– Sell
-5
Closed – – 330
2017
Q4 		$0 Hold
5
– – ﹤0.01% 429
2017
Q3 		$0 Buy
+5
New +$300 ﹤0.01% 479

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Contravisory Investment Management's AGIO Position: Q1 2026 in Review

Contravisory Investment Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 6,189 shares — an estimated $168K sold.

Contravisory Investment Management first reported a position in AGIO in Q3 2017 and held it in 4 quarters. The position peaked at $222K in Q4 2024. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Contravisory Investment Management reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Contravisory Investment Management sold 6,189 Agios Pharmaceuticals shares in Q1 2026, an estimated $168K.
  • Contravisory Investment Management first reported a position in Agios Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Contravisory Investment Management's Agios Pharmaceuticals position peaked at $222K in Q4 2024.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Contravisory Investment Management's 13F filing for Q1 2026, filed 20 Apr 2026.